Croissance des activités réalisées aux laboratoires d’Évry Plan de restructuration et de réduction des coûts lié à l’arrêt des prestations pour le GCS SeqOIA en février Résilience de la...
The discontinuation of services for the SeqOIA platform mechanically led to a 20% reduction in revenues in the first half of the year. Adjusted for this base effect, growth was 6% over the...
Increase in services provided in 2023 by all sequencing platforms, excluding COVID-related activities Positive EBITDA for the third year running, despite inflation impacting reagent costs SeqOIA...
Significant reduction of COVID-19 related activities Growth of all other lines of business Cash totaling €2.9m on Dec 31st, 2023 Laboratory in Évry accredited by the College of American...
Résilience de la rentabilité malgré le contexte inflationniste Croissance des activités aux laboratoires d’Évry Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME...
Baisse de l’activité de la plateforme de séquençage en microbiologie après une forte contribution enregistrée au 1er semestre 2022 dans le cadre de la pandémie de Covid-19. Retraitée de cet...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.03 | 6.57894736842 | 0.456 | 0.52 | 0.448 | 8208 | 0.48725809 | DE |
4 | -0.019 | -3.76237623762 | 0.505 | 0.52 | 0.436 | 7523 | 0.48122268 | DE |
12 | -0.094 | -16.2068965517 | 0.58 | 0.67 | 0.436 | 5604 | 0.50767194 | DE |
26 | -0.119 | -19.6694214876 | 0.605 | 0.705 | 0.436 | 3713 | 0.53463659 | DE |
52 | -0.464 | -48.8421052632 | 0.95 | 0.95 | 0.436 | 4927 | 0.66997537 | DE |
156 | -0.724 | -59.8347107438 | 1.21 | 2.04 | 0.436 | 5165 | 1.15245954 | DE |
260 | -0.472 | -49.2693110647 | 0.958 | 2.67 | 0.436 | 32270 | 1.701426 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.